Infinitopes Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$35M
- Investors
-
19
Infinitopes General Information
Description
Operator of a cancer research company intended for the immune system to prevent metastases and save lives. The company offers a platform that identifies tumor-specific peptides with high accuracy and delivers them via a durable viral vector, enabling oncologists to provide post-surgical relapse prevention for oesophageal cancer patients, ultimately advancing earlier and smarter immunotherapy.
Contact Information
Website
www.infinitopes.comCorporate Office
- Bioescalator Innovation Building, Oxford University
- 696 Roosevelt Drive
- Oxford OX3 7FZ
- England, United Kingdom
Corporate Office
- Bioescalator Innovation Building, Oxford University
- 696 Roosevelt Drive
- Oxford OX3 7FZ
- England, United Kingdom
Infinitopes Timeline
Infinitopes Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Seed Round | 30-Jan-2026 | $35M | Completed | Pre-Clinical Trials | ||
| 7. Early Stage VC (Series A) | 16-Jan-2025 | Cancelled | Clinical Trials - Phase 2 | |||
| 6. Grant | 18-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 06-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 01-Jan-2022 | Cancelled | Startup | |||
| 3. Seed Round | 28-Sep-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 24-Sep-2021 | Completed | Startup |
Infinitopes Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed | ||||||||
| Seed | ||||||||
| Ordinary | 100,000 | $0.000048 | $2.38 | $2.38 | 1x | $2.38 | 1.35% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Infinitopes Comparisons
Industry
Financing
Details
Infinitopes Competitors (5)
One of Infinitopes’s 5 competitors is Epitopea, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Epitopea | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Evaxion | Formerly VC-backed | Hoersholm, Denmark | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Moderna | Formerly VC-backed | Cambridge, MA |
Infinitopes Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Infinitopes Patents
Infinitopes Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024365482-A1 | Compositions and methods for cancer treatment using chimeric viral vectors | Pending | 25-Oct-2023 | ||
| EP-4798230-A2 | Compositions and methods for cancer treatment using chimeric viral vectors | Pending | 25-Oct-2023 | ||
| WO-2025088378-A2 | Compositions and methods for cancer treatment using chimeric viral vectors | Inactive | 25-Oct-2023 | ||
| WO-2025088378-A3 | Compositions and methods for cancer treatment using chimeric viral vectors | Inactive | 25-Oct-2023 | ||
| AU-2024251286-A1 | Methods and compositions for cancer treatment using recombinant polypeptides | Pending | 07-Apr-2023 | A61K39/0011 |
Infinitopes Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Infinitopes Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amplify Partners | Venture Capital | Minority | ||
| Caffeinated Capital | Venture Capital | Minority | ||
| Cancer Research Technology | Venture Capital | Minority | ||
| ECCO (Denmark) | Corporation | Minority | ||
| EMV Capital | Venture Capital | Minority |
Infinitopes FAQs
-
When was Infinitopes founded?
Infinitopes was founded in 2021.
-
Where is Infinitopes headquartered?
Infinitopes is headquartered in Oxford, United Kingdom.
-
What is the size of Infinitopes?
Infinitopes has 20 total employees.
-
What industry is Infinitopes in?
Infinitopes’s primary industry is Drug Discovery.
-
Is Infinitopes a private or public company?
Infinitopes is a Private company.
-
What is Infinitopes’s current revenue?
The current revenue for Infinitopes is .
-
How much funding has Infinitopes raised over time?
Infinitopes has raised $51.1M.
-
Who are Infinitopes’s investors?
Amplify Partners, Caffeinated Capital, Cancer Research Technology, ECCO (Denmark), and EMV Capital are 5 of 19 investors who have invested in Infinitopes.
-
Who are Infinitopes’s competitors?
Epitopea, Evaxion, Genentech, BioNTech, and Moderna are competitors of Infinitopes.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
